Author

K. Chaudagar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Patnaik· 4 shared A. Solanki· 2 shared H. M. Hieromnimon· 2 shared K. Bynoe· 2 shared S. Rameshbabu· 2 shared S. Sharma-Saha· 2 shared A. Kelley· 1 shared A. Swarbrick· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Patnaik

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer

K. Chaudagar, H. M. Hieromnimon, R. Khurana, B. Labadie, T. Heirz, S. Mei, R. Hasan, J. Shafran, A. Kelley, E. Apostolov, G. Al-Eryani, K. Harvey, S. Rameshbabu, M. Loyd, K. Bynoe, , A. Patnaik

The paper shows that inhibiting lactate production in tumor cells suppresses PTEN/p53-deficient prostate cancer growth by activating macrophage phagocytosis.

bioRxiv · May 12, 2022Cancer Biology

BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade

B. Olson, K. Chaudagar, R. Bao, S. Sharma-Saha, C. Hong, S. Rameshbabu, R. Chen, A. Thomas, A. Patnaik

This paper shows that BET inhibition makes immunologically cold Rb-deficient prostate cancer more responsive to immune checkpoint blockade by reprogramming the tumor microenvironment through STING/NF-κB/IFN signaling.

bioRxiv · Mar 24, 2022Cancer Biology

PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

P. D. Gupta, K. Chaudagar, S. Sharma-Saha, K. M. Bynoe, L. Maillat, B. Heiss, W. Stadler, A. Patnaik

This paper shows that combining PARP and PI3K inhibitors eradicates c-MYC-driven prostate cancer by activating the cGAS/STING pathway in tumor-associated macrophages.

bioRxiv · Jul 17, 2020 · PreprintCancer Biology

Cabozantinib unlocks efficient in vivo targeted delivery of neutrophil-loaded nanoparticles into murine prostate tumors

K. Chaudagar, N. Landon-Brace, A. Solanki, H. M. Hieromnimon, E. Hegermiller, W. Li, Y. Shao, D. Wilkins, K. Bynoe, X.-L. Li, J. Clohessy, S. Ullas, J. Karp, A. Patnaik

This study shows cabozantinib enhances neutrophil-mediated delivery of nanoparticles to prostate tumors in mice, leading to higher NP accumulation in the tumor microenvironment.

bioRxiv · Apr 13, 2020Cancer Biology